×
About 2,678 results

ALLMedicine™ Hemochromatosis Center

Research & Reviews  882 results

Evaluation of Patients With Liver Disease
https://clinicaltrials.gov/ct2/show/NCT00001971

Jun 24th, 2022 - This is a general clinical research protocol to allow for evaluation, investigation and long-term follow up of patients who have an acute or chronic liver disease. The protocol is designed to study the natural history and pathogenesis of various l...

Treatment of Hemochromatosis
https://clinicaltrials.gov/ct2/show/NCT00007150

Jun 24th, 2022 - Hereditary hemochromatosis (HH) occurs in 1 in every 200-250 individuals of northern European descent, and is the most common inherited disease in this population. Although the molecular pathophysiology remains incompletely understood, a homozygou...

Cardiac Function in Patients With Hereditary Hemochromatosis
https://clinicaltrials.gov/ct2/show/NCT00068159

Jun 24th, 2022 - Hereditary hemochromatosis (HH) is the most common hereditary metabolic abnormality among Caucasians. Homozygosity for the Cys282Tyr mutation, which is the most common known mutation with a predisposition to iron overload, occurs with an estimated...

Patient-reported outcomes and their relation with iron parameters in HFE haemochromatos...
https://doi.org/10.1111/liv.15341
Liver International : Official Journal of the Internation... Belhomme N, Morcet J et. al.

Jun 22nd, 2022 - The standard of care of hemochromatosis is regular phlebotomy in order to maintain low ferritin levels. Many patients report fatigue or joint pain despite serum ferritin within the therapeutic targets. We evaluated Patient-Reported Outcomes, and t...

Hereditary hemochromatosis variant associations with incident non-liver malignancies: 1...
https://doi.org/10.1158/1055-9965.EPI-22-0284
Cancer Epidemiology, Biomarkers & Prevention : a Publicat... Atkins JL, Pilling LC et. al.

Jun 17th, 2022 - In European ancestry populations, iron overload disorder Hereditary Hemochromatosis (HH) is predominantly caused by HFE p.C282Y and p.H63D mutations. Male p.C282Y homozygotes have markedly increased hepatic malignancy incidence but risks for other...

see more →

Guidelines  5 results

ACG Clinical Guideline: Hereditary Hemochromatosis.
https://doi.org/10.14309/ajg.0000000000000315
The American Journal of Gastroenterology; Kowdley KV, Brown KE et. al.

Jul 25th, 2019 - Hereditary hemochromatosis (HH) is one of the most common genetic disorders among persons of northern European descent. There have been recent advances in the diagnosis, management, and treatment of HH. The availability of molecular diagnostic tes...

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
https://doi.org/10.1038/ajg.2016.517
The American Journal of Gastroenterology; Kwo PY, Cohen SM et. al.

Dec 21st, 2016 - Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests sh...

EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochr...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929861
European Journal of Human Genetics : EJHG; Porto G, Brissot P et. al.

Jul 15th, 2015 - Molecular genetic testing for hereditary hemochromatosis (HH) is recognized as a reference test to confirm the diagnosis of suspected HH or to predict its risk. The vast majority (typically >90%) of patients with clinically characterized HH are ho...

Diagnosis and management of hemochromatosis: 2011 practice guideline by the American As...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149125
Hepatology (Baltimore, Md.); Bacon BR, Adams PC et. al.

Apr 1st, 2011 - Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases.|2011|Bacon BR,Adams PC,Kowdley KV,Powell LW,Tavill AS,|blood,diagnosis,physiopathology,therapy,metabolism,pathology,m...

EASL clinical practice guidelines for HFE hemochromatosis.
https://doi.org/10.1016/j.jhep.2010.03.001
Journal of Hepatology;

May 18th, 2010 - Iron overload in humans is associated with a variety of genetic and acquired conditions. Of these, HFE hemochromatosis (HFE-HC) is by far the most frequent and most well-defined inherited cause when considering epidemiological aspects and risks fo...

see more →

Drugs  16 results see all →

Clinicaltrials.gov  69 results

Treatment of Hemochromatosis
https://clinicaltrials.gov/ct2/show/NCT00007150

Jun 24th, 2022 - Hereditary hemochromatosis (HH) occurs in 1 in every 200-250 individuals of northern European descent, and is the most common inherited disease in this population. Although the molecular pathophysiology remains incompletely understood, a homozygou...

Evaluation of Patients With Liver Disease
https://clinicaltrials.gov/ct2/show/NCT00001971

Jun 24th, 2022 - This is a general clinical research protocol to allow for evaluation, investigation and long-term follow up of patients who have an acute or chronic liver disease. The protocol is designed to study the natural history and pathogenesis of various l...

Cardiac Function in Patients With Hereditary Hemochromatosis
https://clinicaltrials.gov/ct2/show/NCT00068159

Jun 24th, 2022 - Hereditary hemochromatosis (HH) is the most common hereditary metabolic abnormality among Caucasians. Homozygosity for the Cys282Tyr mutation, which is the most common known mutation with a predisposition to iron overload, occurs with an estimated...

Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
https://clinicaltrials.gov/ct2/show/NCT04770870

Jun 14th, 2022 - The Hintermann Series H3® (H3) prosthesis is a mobile bearing total ankle replacement (TAR) indicated for use as a non-cemented implant to replace a painful arthritic ankle joint due to primary osteoarthritis, post-traumatic osteoarthritis or arth...

A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis
https://clinicaltrials.gov/ct2/show/NCT03395704

Jun 9th, 2022 - This study is a Phase 2 multicenter, randomized, placebo controlled, single-blind study. The primary objective of the study is to compare the effect of weekly dosing of LJPC-401 (synthetic human hepcidin) versus placebo on transferrin saturation (...

see more →

News  83 results

Dr. Fitzgerald on Minimizing Use of Chemotherapy in Breast Cancer
https://www.onclive.com/view/dr-fitzgerald-on-minimizing-use-of-chemotherapy-in-breast-cancer

Oct 6th, 2021 - Dennis Fitzgerald, MD, a specialist in breast cancer, lung cancer, non-Hodgkin lymphoma and hemochromatosis, Hackensack Meridian Health Riverview Medical Center, discusses the pivotal TAILORx trial, which found that for intermediate-risk women wit...

Pediatric NAFLD almost always stems from excess body weight, not other etiologies
https://www.mdedge.com/pediatrics/article/238291/obesity/pediatric-nafld-almost-always-stems-excess-body-weight-not-other
Will Pass

Apr 7th, 2021 - Nonalcoholic fatty liver disease (NAFLD) in children is almost always caused by excess body weight, not other etiologies, based on a retrospective analysis of 900 patients. Just 2% of children with overweight or obesity and suspected NAFLD had oth.

Iron Chelation Therapy Efficacy and Safety in MDS
https://www.onclive.com/view/iron-chelation-therapy-efficacy-and-safety-in-mds

Apr 2nd, 2021 - Transcript:James M. Foran, MD, FRCPC: What is the role of the patient in deciding on iron chelation therapy? There are two oral chelating agents—a third one that’s approved in a different setting, deferiprone—and then there’s Desferal, or de...

Negative Effects Associated with Iron Overload
https://www.onclive.com/view/negative-effects-associated-with-iron-overload

Apr 2nd, 2021 - Transcript:David P. Steensma, MD: In patients with congenital anemias, like severe beta thalassemia, it’s clear that iron is a major contributor to morbidity and mortality. If you don’t adequately chelate patients with severe transfusion-defendant...

Diagnosis of HCC: Presentation of Disease
https://www.onclive.com/view/diagnosis-of-hcc-presentation-of-disease

Apr 2nd, 2021 - Transcript: Ghassan K. Abou-Alfa, MD: Hello, and welcome to this OncLive® Peer Exchange® panel discussion titled Global Perspective on Treatment of Hepatocellular Carcinoma. The treatment of advanced hepatocellular carcinoma is complicated by ...

see more →

Patient Education  16 results see all →